From what I understand, Leronlimab blocks CCR5 more effectively than Maraviroc. It should perform much better. From an inflammation viewpoint, Leronlimab should perform better than anything tried (so far).

However, I am not sure if Leronlimab would cause brain swelling and brain bleeding. That appears to be the desired side effect.

Eli Lilly's Alzheimer's candidate has met it's endpoints and shows efficacy, against Alzheimer's Disease, by removing amyloid plaque.

Patients who received donanemab demonstrated a 35% slower decline in memory, thinking and their ability to perform daily activities, according to clinical trial data from its maker, Eli Lilly.
The monthly antibody infusion also significantly reduced brain plaque that is associated with Alzheimer's disease.
Though the results are promising, donanemab also carries a risk of brain swelling and bleeding that in rare cases can be severe and even fatal.
Lilly plans to apply for Food and Drug Administration approval of donanemab as soon as this quarter.


https://www.cnbc.com/2023/05/03/alzheimers-el...ssion.html